- Corporate
Research strategy
Basilea's objective is to maintain a continuous pipeline of innovative candidates
to meet the clinical need for products that have distinct advantages over available
therapies, such as greater efficacy (e.g. cidal activity), especially against
resistant organisms, and better safety, particularly decreased toxicity and risk of
drug-drug interactions.
Basilea pursues a balanced portfolio of pre-clinical programs based on existing and
known compound classes in addition to searching for completely new structures. The
projects address mechanisms essential for cell wall biosynthesis, DNA synthesis and
processing and protein biosynthesis.
Basilea's core competencies in anti-infective research are
genomics, enzyme kinetics, assay development to facilitate high-throughput
screening, microbiology, medicinal chemistry and preclinical PK/PD modelling.
Our approach to generate a continuous pipeline of innovative products is based on:
- focused optimization of compounds that belong to successful antibacterial
classes,
- discovery of novel classes of antibiotic directed at new targets by screening
compound libraries and microbial fermentation broth extracts, and by
structure-based drug design,
- modification of under-exploited antibacterial classes,
- and selective in-licensing and in-house optimization of validated lead compounds
Basilea also possesses considerable assets in dermatology, including a collection
of more than 300 retinoid and vitamin D analogs, and has extensive medicinal
chemistry expertise in this field. These resources are being systematically
explored using a network of collaborations to pursue research opportunities for
several dermatological indications.
© 2010 Basilea Pharmaceutica Ltd.
